Vivek Subbiah, MD, highlights key topics at the 50th European Society for Medical Oncology (ESMO) Congress, including the rise of tumor-agnostic therapies and the use of artificial intelligence (AI) in cancer care.
Vivek Subbiah, MD
Advertisement
Vivek Subbiah, MD, is the chief of early-phase drug development at Sarah Cannon Research Institute.
Articles by Vivek Subbiah, MD
Vivek Subbiah, MD, says artificial intelligence (AI) should assist clinicians in precision oncology, not replace human decision-making.
Artificial intelligence (AI) is expanding clinical trial access and enabling drug repurposing, according to Vivek Subbiah, MD.
Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.
Vivek Subbiah, MD, considers artificial intelligence (AI) and comprehensive somatic and germline testing essential for guiding precision oncology and improving patient care.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials: Christof Vulsteke, MD, PhD
3
Adding Radioligand Therapy Pluvicto to SOC Cuts Risk of Prostate Cancer Progression or Death 28%, but How Many Doses?
4
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
5
